National Institutes of Health (NIH) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Poor sleep linked to migraine attacks in new UArizona Health Sciences study
lburtchbuusTue, 03/12/2024 - 14:42Poor sleep linked to migraine attacks in new UArizona Health Sciences studyImageMarch 13, 2024Byline AffiliationUniversity of Arizona Health SciencesA new study by researchers at theUniversity of Arizona Health Sciences identified a link between poor sleep and migraine attacks that suggests improving sleep health may diminish migraine attacks in people with migraine.Many people with migraine report having sleeping disorders, including insomnia, trouble falling or staying asleep, poor sleep quality, excessive daytime sleepiness, waking up from sleep and being forced to sleep because of a mi...
Source: The University of Arizona: Health - March 12, 2024 Category: Universities & Medical Training Authors: lburtchbuus Source Type: research

Guidance on Race, Ethnicity, and Origin as Proxies for Genetic Ancestry in Biomedical Publication
In March 2023, the National Academies of Sciences, Engineering, and Medicine (NASEM) released a consensus study report titled Using Population Descriptors in Genetics and Genomics Research. Sponsored by the US National Institutes of Health, the report is more than a discussion of the use of terminology; the authors of the NASEM report suggest a tectonic shift away from current models that use race, ethnicity, and geographic origin as proxies for genetic ancestry groups (ie, a set of individuals who share more similar genetic ancestries) in genetic and genomic science. The recommendations are rooted in evidence that genetic...
Source: JAMA - Journal of the American Medical Association - March 12, 2024 Category: General Medicine Source Type: research

Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications
In March 2023, the National Academies of Sciences, Engineering, and Medicine (NASEM) released a consensus study report titled Using Population Descriptors in Genetics and Genomics Research.1 Sponsored by the US National Institutes of Health, the report is more than a discussion of the use of terminology; the authors of the NASEM report suggest a tectonic shift away from current models that use race, ethnicity, and geographic origin as proxies for genetic ancestry groups (i.e., a set of individuals who share more similar genetic ancestries) in genetic and genomic science. (Source: The American Journal of Human Genetics)
Source: The American Journal of Human Genetics - March 12, 2024 Category: Genetics & Stem Cells Authors: W. Gregory Feero, Robert D. Steiner, Anne Slavotinek, Tiago Faial, Michael J. Bamshad, Jehannine Austin, Bruce R. Korf, Annette Flanagin, Kirsten Bibbins-Domingo Tags: Editorial Source Type: research

Ultrasensitive HBsAg Assays-Not Yet Ready for Primetime
This work was supported by the Intramural Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health (Source: Journal of Hepatology)
Source: Journal of Hepatology - March 8, 2024 Category: Gastroenterology Authors: Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee Tags: Letter to the Editor Source Type: research

Can babies infected with HIV be cured? New study offers cautious optimism
More than a decade ago, a Mississippi baby who tested positive for HIV at birth almost immediately started to receive antiretroviral treatment (ART). When a pediatrician saw the girl shortly before her second birthday, she was off the drugs but oddly had no virus detected on standard tests. The so called “Mississippi baby” became an international news story about a potential strategy to cure HIV infections. Pediatrician Deborah Persaud of the Johns Hopkins Children’s Center led the team that reported the Mississippi baby case. At a meeting yesterday, she described similar success with four more children. No one...
Source: Science of Aging Knowledge Environment - March 7, 2024 Category: Geriatrics Source Type: research

Advanced Technologies in Radiation Research
Radiat Res. 2024 Mar 8. doi: 10.1667/RADE-24-00003.1. Online ahead of print.ABSTRACTThe U.S. Government is committed to maintaining a robust research program that supports a portfolio of scientific experts who are investigating the biological effects of radiation exposure. On August 17 and 18, 2023, the Radiation and Nuclear Countermeasures Program, within the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), partnered with the National Cancer Institute, NIH, the National Aeronautics and Space Administration, and the Radiation Injury Treatment Network to convene a workshop titled, ...
Source: Radiation Research - March 7, 2024 Category: Physics Authors: Carmen I Rios Andrea L DiCarlo Lynn Harrison Pataje G S Prasanna Jeffery C Buchsbaum Michael W Rudokas Lauren Gomes Thomas A Winters Source Type: research

New approaches for challenging therapeutic targets
This report highlights key issues discussed during the workshop that, if addressed, could expand the pool of therapeutic approaches for treating various diseases. Teaser Despite successes with new drug approvals, many human diseases remain intractable to conventional therapeutic interventions. This report highlights areas to expand the pool of therapeutic approaches for treating disease discussed at a recent NIH workshop.PMID:38447929 | DOI:10.1016/j.drudis.2024.103942 (Source: Drug Discovery Today)
Source: Drug Discovery Today - March 6, 2024 Category: Drugs & Pharmacology Authors: Karlie R Sharma Abir Malik Rebecca A Roof Jim P Boyce Sharad K Verma Source Type: research

Long-Acting HIV Treatment Superior to Daily Oral Drugs
People with HIV-1 who received a long-acting antiretroviral treatment combining 2 drugs, cabotegravir and rilpivirine, were better able to maintain low levels of the virus compared with those who received daily oral medication, according to interim data, the National Institutes of Health (NIH) announced. The US Food and Drug Administration approved the combination of cabotegravir and rilpivirine, marketed as Cabenuva, as a once-monthly injectable for adults in 2021. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - March 6, 2024 Category: General Medicine Source Type: research

Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression
AbstractThe aim of this study is to explore paroxetine ’s effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-si x patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hyd...
Source: Molecular Neurobiology - March 5, 2024 Category: Neurology Source Type: research

Awareness, knowledge, disease prevention practices, and immunization attitude of hepatitis E virus among food handlers in Klang Valley, Malaysia
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - March 4, 2024 Category: Allergy & Immunology Authors: Sakshaleni RajendiranWong Li PingYuvaneswary VelooSyahidiah Syed Abu Thahira Institute for Medical Research, National Institute of Health, Ministry of Health, Shah Alam, Malaysiab Centre for Epidemiology and Evidence-Based Practice, Department of Social a Source Type: research

Efficacy of migraine prophylaxis treatments for treatment-naïve patients and those with prior treatment failure: a protocol for systematic review and network meta-analysis of randomised controlled trials
This study is a systematic review protocol collecting data from published literature and does not require approval from an institutional review board. Results from this systematic review will be published in a peer-reviewed journal. PROSPERO registration number CRD42020171843. (Source: BMJ Open)
Source: BMJ Open - March 1, 2024 Category: General Medicine Authors: Numthavaj, P., Anothaisintawee, T., Attia, J., McKay, G., Thakkinstian, A. Tags: Open access, Neurology Source Type: research